A population study of 5,893 British adults finds that in early 2025 about 2.9%, roughly 1.6 million people, had used GLP-1 or GLP-1/GIP medications for weight loss in the past year, most commonly Mounjaro, with use highest among women and mid-life adults. A further 6.5% of non-users, about 3.3 million adults, said they would likely consider the drugs, and the authors urge equitable access and regular monitoring as demand grows.